
News|Articles|June 1, 2010
Formulary Digital Edition, June 2010
Pulmonary arterial hypertension: Bridging the gap between efficacy, quality of life, and cost-effectiveness; Lorcaserin: A novel, selective 5-HT2C-receptor agonist for the treatment of obesity; Vaccine agents in late-stage development.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Zepbound linked to lower healthcare costs in older adults with obesity
2
FDA approves Gilead’s Bixlenvo, smallest single-tablet option for virologically suppressed HIV patients
3
FDA approves brepocitinib for rare skin disease
4
Biosimilars provide modest cost savings for cancer patients, study finds
5













